NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. (NASDAQ: AARD):

- Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders should email [email protected]

What is the Investigation About?

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases. It is alleged that the company, or certain of its officers, overstated the safety and clinical prospects of its lead drug candidate, ARD-101, including by representing that the drug had minimal systemic exposure and had resulted in no serious adverse events.

On February 27, 2026, Aardvark announced that it was pausing its Phase 3 HERO trial after cardiac observations were identified during a healthy-volunteer study. Its stock price subsequently fell $7.02 per share, or approximately 56.2%, to close at $5.47 per share on March 2, 2026. On May 14, 2026, the company announced that the FDA had placed a full clinical hold on ARD-101. Its stock fell an additional $2.16 per share, or approximately 32.1%, to close at $4.57 per share on May 15, 2026.

If you own Aardvark Therapeutics, Inc. (NASDAQ: AARD) please contact Fletcher Moore at [email protected].

You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court-approved incentive award at no cost to you whatsoever. All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

MOORE LAW PLLC

30 Wall Street, 8th Floor

New York, NY 10005

[email protected]

www.fmoorelaw.com

SOURCE Moore Law PLLC

Share this article